

The Burden of ASCVD

Cardiovascular disease (CVD) currently is the number one cause of death in the US annually, surpassing all types of cancer, unintentional injury and stroke¹



CVD prevalence is expected to rise, affecting a projected 45% of the US population by 2035²



1 in 4 heart attacks and strokes are recurrent events³

CVD places a greater economic burden on the US healthcare system than any other single class of disease²



The total direct and indirect cost of CVD in the US was **\$555 billion** in 2016, and it's projected to reach **\$1.1 trillion by 2035²**

As a chronic disease, CVD has a significant personal and societal impact



- Obstacles that can complicate lifestyle, treatment and access to care may include: socioeconomic status, decline in health evaluations due to COVID-19 and limited health literacy⁴⁻⁹.
- Certain groups, including minorities, women and rural communities, experience significant disparities in CVD care and poorer outcomes¹⁰.
- Research done in 2017 showed that non-Hispanic Black persons had death rates from CVD 20% or greater compared to other racial and ethnic groups¹¹.



Atherosclerotic CVD (ASCVD) accounts for the majority of CVD cases¹²

ASCVD can cause recurrent events like heart attack or stroke¹³

The risk of developing ASCVD increases the longer a patient is exposed to elevated LDL-C levels¹⁴

Although low-density lipoprotein cholesterol (LDL-C, or "bad" cholesterol) is the most readily modifiable risk factor for ASCVD, current treatment approaches are not enough. As of 2020, of the estimated 20 million Americans with ASCVD who are being treated with a statin, **80%** - or **16 million** - struggle to reach the recommended LDL-C goal¹⁵.

Inability to access treatments other than statins can prevent ASCVD patients from properly managing elevated LDL-C^{4,7}.

As of 2020, **~30 million people** in the US were living with some form of ASCVD¹⁵⁻¹⁷.



Maintaining low LDL-C levels is vital to help reduce the risk of complications like a heart attack or stroke and a diagnosis of ASCVD¹⁸.



**How to bend the curve of CVD:
help patients better control their LDL-C levels**

REFERENCES

1. Ahmad FB, et al. The leading causes of death in the US for 2020. *JAMA*. 2021;325(18):1829-1830.
2. American Heart Association/American Stroke Association. Cardiovascular disease: a costly burden. Accessed September 29, 2021. https://www.heart.org/idc/groups/heart-public/@wcm/@adv/documents/downloadable/ucm_491543.pdf
3. Virani SS, et al. Heart Disease and Stroke Statistics—2021 Update: A report from the American Heart Association. *Circulation*. 2021;143(8):e254–e743.
4. Jones PH, et al. Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: a retrospective analysis. *J Am Heart Assoc*. 2012;1(6):e001800.
5. Jacobson TA, et al. The STatin Adverse Treatment Experience Survey: experience of patients reporting side effects of statin therapy. *J Clin Lipidol*. 2019;13(3):415-424.
6. Lansberg P, et al. Nonadherence to statins: individualized intervention strategies outside the pill box. *Vasc Health Risk Manag*. 2018;14:91-102.
7. Brown MT, et al. Medication adherence: WHO cares? *Mayo Clin Proc*. 2011;86(4):304-314. doi:10.4065/mcp.2010.0575.
8. Office of Disease Prevention and Health Promotion. Social determinants of health. *Healthy People 2030*. Accessed September 29, 2021. <https://health.gov/healthypeople/objectives-and-data/social-determinants-health>
9. Miller K. Cleveland Clinic survey: about half of Americans experiencing concerning heart symptoms during pandemic avoid seeking care. *Clevelandclinic.org*. Published February 1, 2021. Accessed September 29, 2021. <https://newsroom.clevelandclinic.org/2021/02/01/cleveland-clinic-survey-about-half-of-americans-experiencing-concerning-heart-symptoms-during-pandemic-avoid-seeking-care/>
10. Graham G. Disparities in cardiovascular disease risk in the United States. *Curr Cardiol Rev*. 2015;11(3):238-245.
11. Centers for Disease Control and Prevention. Health, United States Spotlight: Racial and Ethnic Disparities in Heart Disease. April 2019. Accessed September 29, 2021. https://www.cdc.gov/nchs/spotlight/HeartDiseaseSpotlight_2019_0404.pdf
12. Frostegård J. Immunity, atherosclerosis and cardiovascular disease. *BMC Med*. 2013;11:117-133.
13. Centers for Disease Control and Prevention. Heart Disease Facts. Accessed September 29, 2021. <https://www.cdc.gov/heartdisease/facts.htm>
14. Ference BA, et al. Impact of lipids on cardiovascular health: JACC Health Promotion Series. *J Am Coll Cardiol*. 2018;72(10):1141-1156.
15. Wong ND, et al. Prevalence of the American College of Cardiology/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US adults using the National Health and Nutrition Examination Survey 2011-2012. *J Clin Lipidol*. 2016;10(5):1109-1118.
16. Benjamin EJ, et al. Heart Disease and Stroke Statistics—2019 Update: A report from the American Heart Association. *Circulation*. 2019;139(10):e56-e28.
17. Selvin E, et al. Contemporary risk factor control and walking dysfunction in individuals with peripheral arterial disease: NHANES 1999-2004. *Atherosclerosis*. 2008;201(2):425-433.
18. Silverman M, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. *JAMA*. 2016;316(12):1289-1297.